当前位置:首页 > 报告详情

Ross - Telemedicine in DR screening.pdf

上传人: 彩旗 编号:1158782 2026-03-02 12页 1.72MB

1、Current Practices and Future Prospects:Telemedicine in Diabetic Retinopathy ScreeningJonathon Ross,OD,MS,FAAOAssistant Clinical ProfessorFinancial disclosures NoneObjectives Epidemiology Diabetes and vision loss Models for retinal screening Traditional Hybrid AI Barriers for AI retinal screeningEpid

2、emiology Diabetes prevalence World(2024)Adults 589 million1(10%)US(2024)Adults 38 million2(11.5%)Seniors 16.5 million2(29%)1.IDF Diabetes Atlas 2025.11th Edition.2025.https:/diabetesatlas.org/resources/idf-diabetes-atlas-2025/2.American Diabetes Association.2025.https:/diabetes.org/about-diabetes/st

3、atistics/about-diabetes.US fiscal impact US annual cost of vision impairment and blindness due to diabetes(2023)Direct health costs=$306 billion1 Indirect health costs=$106 billion1 Total health costs=$412 billion11.Statistics.American Diabetes Association.2023.https:/diabetes.org/about-us/statistic

4、sComplications of diabetes Systemic complications1 Blindness Kidney failure Heart attack Stroke Limb amputation Ocular complications Diabetic retinopathy#1 cause of preventable vision impairment and blindness in working age adults2 Incidence 1 in 3 patients with diabetes21.Diabetes Fact Sheet.WHO.20

5、23.https:/www.who.int/health-topics/diabetes#tab=tab_12.Statistics.American Diabetes Association.2023.https:/diabetes.org/about-us/statisticsDiabetic retinopathy(DR)Clinical findings1 Damage to all layers of the retina,including the macula Progression risk factors2 Duration of disease Hyperglycemia

6、Hypertension Hyperlipidemia Nephropathy Pregnancy1.Diabetic Retinopathy.Retinal vascular disease.Chapter 13.Kanskis Clinical Ophthalmology.8th Edition.Elsevier,Sydney Australia2.Klein et.al.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.Arch Ophthal

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **流行病学与经济负担**:全球糖尿病患者约5.89亿(占成人10%),美国3820万(11.5%);2023年美国糖尿病相关视力损害直接成本3060亿美元,总成本4120亿美元。 2. **糖尿病视网膜病变(DR)风险**:DR是工作人群可预防视力损害的首要原因,1/3糖尿病患者患病,但仅不足50%完成年度筛查。 3. **筛查模式**:传统、混合及人工智能(AI)模式,AI代表IDx-DR(2018年获批),敏感性87.4%,特异性89.5%,图像获取率96%。 4. **AI筛查障碍**:盈利性、公平性与算法偏见(如“黑箱”问题)。
**AI筛查可靠吗?** **糖网筛查现状?** **AI筛查障碍?**
客服
商务合作
小程序
服务号
折叠